Bruderman Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bruderman Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-160	Closed	-$5K	–	143
2019 Q1	$5K	Buy	160 +2	+1%	+$59	﹤0.01%	480
2018 Q4	$4K	Buy	+158	New	+$4.45K	﹤0.01%	501

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CFA

Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

SCA

Snowden Capital Advisors New York $4.23B AUM 29.95% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Stephens Inc Little Rock, Arkansas $8.93B AUM 25.13% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Bruderman Asset Management's ARKG Position: Q2 2019 in Review

Bruderman Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2019, closing a stake of 160 shares — an estimated $5K sold.

Bruderman Asset Management first reported a position in ARKG in Q4 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 72 funds tracked by Wall St. Rank hold ARKG as of Q2 2019.

Bruderman Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q2 2019 after selling out during the quarter.
Bruderman Asset Management sold 160 ARK Genomic Revolution ETF shares in Q2 2019, an estimated $5K.
Bruderman Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2018 and held it in 2 quarters.
Bruderman Asset Management's ARK Genomic Revolution ETF position peaked at $5K in Q1 2019.
72 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.